Biogen sues Teva over MS generic
18-03-2021
Biogen to pay $1.25bn to Forward Pharma in licensing deal
19-01-2017
Avosb / iStockphoto.com
Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Biogen, dismiss, competition, Ixchel Pharma, Forward Pharma, anti-competition, patent
